The firm plans to spend an initial $4.5m (€3.4m) to kit-out the 19,000 sq ft plant, which will focus on development and analytics. A further 13,000 sq ft on the site will be used for future expansion.
CEO Paul Bisaro said the facility’s location in North Brunswick was chosen to establish bonds with “educational centres of excellence as Rutgers University”.
The company has also been expanding its generics offering after taking over Strides’ Australian subsidiary Ascent Pharmahealth.
Shortly afterwards, Watson was granted a stay of the preliminary injunction, which was blocking it from marketing a generic version of Sanofi’s deep vein thrombosis medication, Lovenox.